Dr Doreen Zhu
Research groups
Doreen Zhu
MD
Academic Clinical Lecturer
Doreen is an academic clinical lecturer based in the Renal Studies Group at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) and in the Oxford Kidney Unit at Oxford University Hospitals.
She studied pre-clinical medicine at the University of Cambridge and clinical medicine at the University in Oxford before commencing clinical training in the Wessex deanery.
In August 2016, she started specialty training in Renal and General Internal Medicine in the Thames Valley Deanery before she was appointed as a clinical research fellow in 2018 for three years.
During this time, she completed a MD exploring the associations of blood pressure with kidney outcomes in the Mexico City Prospective Study and worked on the EMPA-KIDNEY trial, which tested whether empagliflozin prevents worsening of kidney disease or deaths from heart disease in people with chronic kidney disease.
For her postdoctoral research, she hopes to study the associations of genetically-predicted risk factors with kidney outcomes, explore metabolomic and proteomic risk factors for kidney disease, and to develop her knowledge and experience of clinical trials, testing new treatments aimed at managing and reducing the progression of chronic kidney disease.
Recent publications
-
Design considerations for future renoprotection trials in
the era of multiple therapies for chronic kidney disease
Journal article
ZHU D. et al, (2024), NDT International
-
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Nephrol Dial Transplant
-
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
-
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Journal article
Zhu D. et al, (2024), Am J Kidney Dis, 83, 427 - 428
-
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50